A Phase 3 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Terminated at 184 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 6th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 830 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 778 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Are receiving at least one of the following standard of care medications for SLE:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two placebo tablets: one matching baricitinib 4 milligram (mg) and one matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
Drug: Placebo
Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
Drug: Baricitinib · Drug: Placebo
Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
Drug: Baricitinib · Drug: Placebo
Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.
Drug: Placebo
Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
Drug: Baricitinib · Drug: Placebo
Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
Drug: Baricitinib · Drug: Placebo
Administered orally.
Also known as: LY3009104
Administered orally.
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)
SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
Time frame: Week 52
Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib
SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
Time frame: Week 52
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.
Time frame: Week 52
Time to First Severe Flare
Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 \[SLEDAI-2K \] \<10; SLEDAI-2K ≥10), baseline corticosteroid dose (\<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time.
Time frame: Baseline to Week 52
Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline
For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52.
Time frame: Baseline, Week 40 through Week 52
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)
Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline, Week 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score
FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline, Week 52
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.
Time frame: Week 52
Change From Baseline in Tender Joints Count
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline, Week 52
Change From Baseline in Swollen Joint Count
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline, Week 52
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)
PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach.
Time frame: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach.
Time frame: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
| Milestone | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|---|---|---|---|---|---|---|
| Started | 257 | 258 | 254 | 21 | 20 | 20 |
| Received at least one dose of study drug | 257 | 256 | 254 | 21 | 20 | 20 |
| Excluded due to site misconduct | 4 | 1 | 2 | 0 | 0 | 0 |
| Completed | 204 | 211 | 208 | 5 | 5 | 6 |
| Not completed | 53 | 47 | 46 | 16 | 15 | 14 |
| Withdrew: Adverse event | 17 | 21 | 9 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 13 | 6 | 8 | 4 | 5 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Due to epidemic/pandemic | 4 | 2 | 5 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 12 | 15 | 2 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 10 | 9 | 11 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized but never treated | 0 | 2 | 0 | 0 | 0 | 0 |
SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
| percentage of participants | Placebo | 4 mg Baricitinib |
|---|---|---|
| Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) | 45.9 | 56.7 |
SRI-4 response defined as 1)greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
| percentage of participants | Placebo | 2 mg Baricitinib |
|---|---|---|
| Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib | 45.9 | 49.8 |
The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.
| percentage of participants | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS) | 26.2 | 25.7 | 29.7 |
Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 \[SLEDAI-2K \] \<10; SLEDAI-2K ≥10), baseline corticosteroid dose (\<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time.
| weeks | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Time to First Severe Flare | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52.
| percentage of participants | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline | 30.8 | 29.2 | 34.0 |
Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| score on a scale | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in Worst Pain Numeric Rating Scale (NRS) | -1.62 ± 0.15 | -1.73 ± 0.15 | -1.71 ± 0.15 |
FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| score on a scale | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score | 7.44 ± 0.62 | 7.46 ± 0.60 | 7.08 ± 0.61 |
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.
| percentage of participants | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score | 49.0 | 54.3 | 55.8 |
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| tender joint count | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in Tender Joints Count | -7.50 ± 0.312 | -7.26 ± 0.305 | -7.94 ± 0.307 |
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| swollen joint count | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in Swollen Joint Count | -5.37 ± 0.201 | -5.67 ± 0.196 | -5.81 ± 0.198 |
PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach.
| hour*nanograms per milliliter (h*ng/mL) | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|
| Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) | 256 ± 52 | 502 ± 52 |
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach.
| nanograms per milliliter (ng/mL) | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|
| Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) | 26.7 ± 24 | 53.0 ± 23 |
Collected over Baseline through Follow-up (Up to 56 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/253 (0.4%) | 19/253 (7.5%) | 129/253 (51%) |
| 2 mg Baricitinib | 1/255 (0.4%) | 27/255 (10.6%) | 144/255 (56.5%) |
| 4 mg Baricitinib | 0/252 (0%) | 31/252 (12.3%) | 144/252 (57.1%) |
| Placebo Maximum Extended Enrollment (MEE) | 0/21 (0%) | 1/21 (4.8%) | 17/21 (81%) |
| 2 mg Baricitinib (MEE) | 0/20 (0%) | 4/20 (20%) | 14/20 (70%) |
| 4 mg Baricitinib (MEE) | 0/20 (0%) | 3/20 (15%) | 17/20 (85%) |
| Event | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|---|---|---|---|---|---|---|
| Cholecystitis chronicHepatobiliary disorders | 0/253 | 0/255 | 0/252 | 0/21 | 0/20 | 1/20 |
| CholelithiasisHepatobiliary disorders | 0/253 | 1/255 | 0/252 | 0/21 | 0/20 | 1/20 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/253 | 0/255 | 0/252 | 0/21 | 1/20 | 0/20 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/253 | 1/255 | 4/252 | 0/21 | 1/20 | 1/20 |
| Haemangioma of liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/253 | 0/255 | 0/252 | 0/21 | 1/20 | 0/20 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/237 | 0/238 | 1/237 | 0/20 | 0/19 | 1/20 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/253 | 0/255 | 0/252 | 0/21 | 1/20 | 0/20 |
| Lupus nephritisRenal and urinary disorders | 1/253 | 2/255 | 1/252 | 1/21 | 0/20 | 0/20 |
| PneumoniaInfections and infestations | 0/253 | 4/255 | 2/252 | 0/21 | 0/20 | 0/20 |
| Ankle fractureInjury, poisoning and procedural complications | 0/253 | 0/255 | 2/252 | 0/21 | 0/20 | 0/20 |
| Event | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 17/253 | 21/255 | 19/252 | 5/21 | 9/20 | 7/20 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 4/253 | 9/255 | 3/252 | 5/21 | 0/20 | 1/20 |
| HyperlipidaemiaMetabolism and nutrition disorders | 1/253 | 2/255 | 6/252 | 3/21 | 4/20 | 3/20 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/253 | 2/255 | 2/252 | 2/21 | 3/20 | 4/20 |
| Urinary tract infectionInfections and infestations | 25/253 | 32/255 | 37/252 | 2/21 | 3/20 | 1/20 |
| DizzinessNervous system disorders | 4/253 | 1/255 | 5/252 | 0/21 | 1/20 | 3/20 |
| AnaemiaBlood and lymphatic system disorders | 4/253 | 4/255 | 13/252 | 3/21 | 2/20 | 2/20 |
| LymphopeniaBlood and lymphatic system disorders | 10/253 | 11/255 | 9/252 | 3/21 | 1/20 | 1/20 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/253 | 4/255 | 0/252 | 2/21 | 0/20 | 2/20 |
| HypothyroidismEndocrine disorders | 1/253 | 1/255 | 0/252 | 0/21 | 2/20 | 0/20 |
All randomized participants who receive at least one dose of study drug. One investigational site with seven participants was excluded from analysis due to confirmed misconduct.
| Age, Continuous(years) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib MEE | 4 mg Baricitinib MEE | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.00 ± 11.98 | 42.90 ± 12.44 | 41.50 ± 12.88 | 32.90 ± 10.83 | 37.70 ± 11.38 | 34.60 ± 8.31 | 41.60 ± 12.43 |
| Sex: Female, Male(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib MEE | 4 mg Baricitinib MEE | Total |
|---|---|---|---|---|---|---|---|
| Female | 237 | 238 | 237 | 20 | 19 | 20 | 771 |
| Male | 16 | 17 | 15 | 1 | 1 | 0 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib MEE | 4 mg Baricitinib MEE | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 13 | 11 | 0 | 0 | 0 | 28 |
| Not Hispanic or Latino | 42 | 35 | 38 | 0 | 0 | 0 | 115 |
| Unknown or Not Reported | 207 | 207 | 203 | 21 | 20 | 20 | 678 |
| Race (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib MEE | 4 mg Baricitinib MEE | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 12 | 15 | 7 | 0 | 0 | 0 | 34 |
| Asian | 33 | 39 | 34 | 21 | 20 | 20 | 167 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 36 | 23 | 30 | 0 | 0 | 0 | 89 |
| White | 168 | 172 | 177 | 0 | 0 | 0 | 517 |
| More than one race | 1 | 2 | 0 | 0 | 0 | 0 | 3 |
| Unknown or Not Reported | 3 | 4 | 4 | 0 | 0 | 0 | 11 |
| Region of Enrollment(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib MEE | 4 mg Baricitinib MEE | Total |
|---|---|---|---|---|---|---|---|
| Australia | 10 | 9 | 12 | 0 | 0 | 0 | 31 |
| Austria | 0 | 1 | 2 | 0 | 0 | 0 | 3 |
| Belgium | 2 | 1 | 1 | 0 | 0 | 0 | 4 |
| Brazil | 38 | 22 | 23 | 0 | 0 | 0 | 83 |
| China | 16 | 21 | 18 | 21 | 20 | 20 | 116 |
| Croatia | 5 | 3 | 2 | 0 | 0 | 0 | 10 |
| Czechia | 18 | 11 | 9 | 0 | 0 | 0 | 38 |
| Germany | 14 | 14 | 17 | 0 | 0 | 0 | 45 |
| Greece | 4 | 9 | 5 | 0 | 0 | 0 | 18 |
| Hungary | 13 | 18 | 19 | 0 | 0 | 0 | 50 |
| Israel | 1 | 3 | 4 | 0 | 0 | 0 | 8 |
| Mexico | 36 | 51 | 49 | 0 | 0 | 0 | 136 |
| Netherlands | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Russia | 26 | 25 | 20 | 0 | 0 | 0 | 71 |
| Switzerland | 3 | 2 | 3 | 0 | 0 | 0 | 8 |
| Taiwan | 15 | 11 | 13 | 0 | 0 | 0 | 39 |
| United Kingdom | 5 | 4 | 4 | 0 | 0 | 0 | 13 |
| United States | 47 | 49 | 50 | 0 | 0 | 0 | 146 |
Showing the first 100 of 184 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · trials.lillytrialguide.com
Ran from Aug 2018 to primary completion in Nov 2021, 38 months.
Results were first posted in Jan 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Lupus Erythematosus, Systemic →